Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | LPL | P06858 | 6/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | F11 | P03951 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28621374 | 0.86 | LIPG (0.52) | MEN1KMT2ALPLLIPGF11 | |
| SCHEMBL3447467 | 0.86 | RAB9A (0.66) | ALDH1A1NPC1RAB9AKDM4EMAPT | |
| SCHEMBL12459046 | 0.86 | RAB9A (0.66) | ALDH1A1NPC1RAB9AKDM4EMAPT | |
| SCHEMBL20745563 | 0.84 | LMNA (0.51) | MEN1KMT2ALPLLIPGALDH1A1 | |
| SCHEMBL429722 | 0.84 | LMNA (0.53) | LPLLIPGALDH1A1NPC1F11 | |
| SCHEMBL1354581 | 0.84 | LPL (0.54) | LPLLIPGALDH1A1F11KDM4E | |
| SCHEMBL3319981 | 0.84 | LPL (0.54) | LPLLIPGALDH1A1F11KDM4E | |
| SCHEMBL427977 | 0.82 | HRH3 (0.56) | MEN1KMT2ALPLLIPGALDH1A1 | |
| SCHEMBL2800781 | 0.82 | KMT2A (0.41) | MEN1KMT2ALPLLIPGALDH1A1 | |
| SCHEMBL25153288 | 0.82 | LPL (0.49) | LPLLIPGF11ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | GIVAUDAN SA (CH) | 2026-04-16 | — | — | US | disclosed |
| US-12558360-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | ALFASIGMA S.P.A. (IT) | 2026-02-24 | — | — | US | disclosed |
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | GIVAUDAN SA (CH) | 2026-01-20 | — | — | US | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250289816-A1 | SALTS AND PHARMACUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ALFASIGMA S.P.A. (IT) | 2025-09-18 | — | — | US | disclosed |
| US-12234235-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | ALFASIGMA S.P.A. (IT) | 2025-02-25 | — | — | US | disclosed |
| US-20240368161-A1 | CYCLOPROPANECARBOXAMIDE-CONTAINING COMPOUNDS AND APPLICATION THEREOF | CGENETECH (SUZHOU,CHINA) CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4446322-A1 | CYCLOPROPANAMIDE-CONTAINING COMPOUND AND USE THEREOF | CGeneTech (Suzhou, China) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| US-20240325405-A1 | COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2024-10-03 | — | — | US | disclosed |
| US-12042498-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | ALFASIGMA S.P.A. (IT) | 2024-07-23 | — | — | US | disclosed |
| WO-2010149769-A1 | 5-PHENYL-[1,2,4 ]TRIAZOLO[1,5-A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010149769-A1 | 5-PHENYL-[1,2,4 ]TRIAZOLO[1,5-A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-12-29 | — | — | WO | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010184-A1 | [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010189-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | TRPM8, TRPM7, TRPM5 | MEN1 1252/4885KMT2A 2019/4885LPL 2835/4885 |
| US-20240325405-A1 | COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, BMP6, JAK1 | MEN1 3750/4885KMT2A 4328/4885LPL 4281/4885 |
| US-12558360-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | JAK1, IL6, STAT3 | MEN1 2770/4885KMT2A 4074/4885LPL 4489/4885 |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | MEN1 2485/4885KMT2A 813/4885LPL 4859/4885 |
| US-20240368161-A1 | CYCLOPROPANECARBOXAMIDE-CONTAINING COMPOUNDS AND APPLICATION THEREOF | MCL1, BCL9, BCL9L | MEN1 888/4885KMT2A 2995/4885LPL 3589/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | MEN1 154/4885KMT2A 1365/4885LPL 4440/4885 |
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | TRPM8, TRPM7, TRPM4 | MEN1 1271/4885KMT2A 2021/4885LPL 2903/4885 |
| US-12234235-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL6, JAK1, COL1A1 | MEN1 1984/4885KMT2A 4752/4885LPL 4396/4885 |
| US-12042498-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | IL6, JAK1, BMP6 | MEN1 3505/4885KMT2A 4322/4885LPL 4625/4885 |
| US-20250289816-A1 | SALTS AND PHARMACUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL6, JAK1, BMP6 | MEN1 2647/4885KMT2A 4704/4885LPL 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.